Preclinical Evaluation of Novel Combinations of 177-Lutetium Octreotate with Molecular Targeted Agents in Neuroendocrine Tumor Models

#613

Introduction: Peptide receptor radionuclide therapy (PRRT) has been valuable in the treatment of somatostatin receptor-2 (SSTR2) expressing neuroendocrine tumors (NET) but more effective clinical regimens are needed.

Aim(s): To develop preclinical NET models and use these to identify novel therapeutic regimens combining radiosensitizing agents and PRRT with improved efficacy for evaluation in the clinical setting.

Materials and methods: We have characterized a panel of NET cell lines for their SSTR2 mRNA and protein expression, in vivo growth properties, in vivo uptake of the PET imaging tracers, FDG and Ga-68 octreotate and in vivo sensitivity to Lu-177 octreotate (Lutate) and a range of chemotherapy drugs.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author: Cullinane C

Authors: Cullinane C, Waldeck K, Kirby L, Eu P, Hicks R,

Keywords: preclinical models, PRRT, radiosensitizer,